Skip to main content

Emerging Therapeutics

Section edited by Gennaro Ciliberto

© Parilov / stock.adobe.comThe Emerging Therapeutics section is dedicated to the wave of emerging therapeutics arising from the intense research efforts and therapeutic breakthroughs based on recent scientific and technological developments. 

The section is interested in original papers, reviews and perspectives on the advancements in the field, including genetic vaccines, monoclonal antibodies, CAR-Ts, gene therapy with viral vectors, clinical applications of CRISPR/CAS9 gene editing, microbiota-modulating approaches, ‘omics approaches, emerging therapeutics from the development of new technologies for drug development, and discovery of new intervention targets and the possibility for new drug combinations.

  1. Mutated and non-mutated genes interact to drive cancer growth and metastasis. While research has focused on understanding the impact of mutated genes on cancer biology, understanding non-mutated genes that are...

    Authors: Halema Al-Farsi, Iman Al-Azwani, Joel A. Malek, Lotfi Chouchane, Arash Rafii and Najeeb M. Halabi
    Citation: Journal of Translational Medicine 2022 20:244
  2. The Great Debate session at the 2021 Melanoma Bridge virtual congress (December 2–4) featured counterpoint views from experts on seven important issues in melanoma. The debates considered the use of adoptive c...

    Authors: Paolo A. Ascierto, Allison Betof Warner, Christian Blank, Corrado Caracò, Sandra Demaria, Jeffrey E. Gershenwald, Nikhil I. Khushalani, Georgina V. Long, Jason J. Luke, Janice M. Mehnert, Caroline Robert, Piotr Rutkowski, Hussein A. Tawbi, Iman Osman and Igor Puzanov
    Citation: Journal of Translational Medicine 2022 20:200
  3. In this study we aimed to investigate signaling pathways that drive therapy resistance in esophageal adenocarcinoma (EAC). Paraffin-embedded material was analyzed in two patient cohorts: (i) 236 EAC patients w...

    Authors: A. Creemers, A. P. van der Zalm, A. van de Stolpe, L. Holtzer, M. Stoffels, G. K. J. Hooijer, E. A. Ebbing, H. van Ooijen, A. G. C. van Brussel, E. M. G. Aussems-Custers, M. I. van Berge Henegouwen, M. C. C. M. Hulshof, J. J. G. H. M. Bergman, S. L. Meijer, M. F. Bijlsma and H. W. M. van Laarhoven
    Citation: Journal of Translational Medicine 2022 20:183
  4. Exosomes are microvesicles secreted by cells. They contain a variety of bioactive substances with important roles in intercellular communication. Circular RNA (circRNA), a type of nucleic acid molecule found i...

    Authors: Dong Ye, Mengdan Gong, Yongqin Deng, Shuai Fang, Yujie Cao, Yizhen Xiang and Zhisen Shen
    Citation: Journal of Translational Medicine 2022 20:161
  5. JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated. Here, we aim to determine the effect and underlying mech...

    Authors: Zhenghui Song, Xinhui Liu, Wan Zhang, Yue Luo, Hua Xiao, Yun Liu, Guanqi Dai, Jian Hong and Aimin Li
    Citation: Journal of Translational Medicine 2022 20:157
  6. Urokinase-type plasminogen activator receptor (uPAR) is an attractive target for the treatment of cancer, because it is expressed at low levels in healthy tissues but at high levels in malignant tumours. uPAR ...

    Authors: Bing-Tao Zhai, Huan Tian, Jing Sun, Jun-Bo Zou, Xiao-Fei Zhang, Jiang-Xue Cheng, Ya-Jun Shi, Yu Fan and Dong-Yan Guo
    Citation: Journal of Translational Medicine 2022 20:135
  7. Lenvatinib is a multitargeted tyrosine kinase inhibitor that is being tested in combination with immune checkpoint inhibitors to treat advanced gastric cancer; however, little data exists regarding the efficac...

    Authors: John D. Karalis, Lynn Y. Yoon, Suntrea T. G. Hammer, Changjin Hong, Min Zhu, Ibrahim Nassour, Michelle R. Ju, Shu Xiao, Esther C. Castro-Dubon, Deepak Agrawal, Jorge Suarez, Scott I. Reznik, John C. Mansour, Patricio M. Polanco, Adam C. Yopp, Herbert J. Zeh III…
    Citation: Journal of Translational Medicine 2022 20:116
  8. Gastric cancer (GC) is one of the most common malignancies, and an increasing number of studies have shown that its pathogenesis is regulated by various miRNAs. In this study, we investigated the role of miR-8...

    Authors: Shenshuo Gao, Zhikai Zhang, Xubin Wang, Yan Ma, Chensheng Li, Hongjun Liu, Changqing Jing, Leping Li and Xiaobo Guo
    Citation: Journal of Translational Medicine 2022 20:115
  9. Cardiovascular impairment contributes to increased mortality in preterm infants with chronic lung disease. Macitentan, an endothelin-1 receptor antagonist, has the potential to attenuate pulmonary and cardiova...

    Authors: Philipp Baumann, Francesco Greco, Susanne Wiegert, Sven Wellmann, Giovanni Pellegrini and Vincenzo Cannizzaro
    Citation: Journal of Translational Medicine 2022 20:77
  10. Glioblastoma is currently an incurable cancer. Genome-wide association studies have demonstrated that 41 genetic variants are associated with glioblastoma and may provide an option for drug development.

    Authors: Wei-Zhi Lin, Yen-Chun Liu, Meng-Chang Lee, Chi-Tun Tang, Gwo-Jang Wu, Yu-Tien Chang, Chi-Ming Chu and Chia-Yang Shiau
    Citation: Journal of Translational Medicine 2022 20:70
  11. Young patients with colorectal cancer (CRC) exhibit poor prognoses compared to older patients due to the difficulty in early diagnosis and treatment. However, the underlying molecular characteristics are still...

    Authors: Tae Won Kim, Hye Kyung Hong, Chung Lee, Sunmin Kim, Woo Yong Lee, Seong Hyeon Yun, Hee Cheol Kim, Jung Wook Huh, Yoon Ah Park, Je-Gun Joung, Woong-Yang Park and Yong Beom Cho
    Citation: Journal of Translational Medicine 2021 19:446
  12. The lectin galactoside-binding soluble 3 binding protein (LGALS3BP) is a secreted, hyperglycosylated protein expressed by the majority of human cells. It was first identified as cancer and metastasis associate...

    Authors: Emily Capone, Stefano Iacobelli and Gianluca Sala
    Citation: Journal of Translational Medicine 2021 19:405
  13. Poorly cohesive (PC) is a unique histologic subtype of gastric cancer (GC), with an increasing incidence in recent years. However, the molecular characteristics and therapeutic targets of PC GC are not yet wel...

    Authors: Yue Wang, Tao Shi, Xuan Wang, Jinwei Hu, Lixia Yu, Qin Liu, Nandie Wu, Baorui Liu and Jia Wei
    Citation: Journal of Translational Medicine 2021 19:401
  14. Recent studies have showed that IKBKE is overexpressed in several kinds of cancers and that IKBKE-knockdown inhibits tumor progression. In this article, we first verified that two glioblastoma cell lines, U87-...

    Authors: Xin Wang, Jie Lu, Jing Li, Yang Liu, Gaochao Guo and Qiang Huang
    Citation: Journal of Translational Medicine 2021 19:396
  15. Lung adenocarcinoma (LUAD) is a common subtype of lung cancer with high recurrence rate and fatality. Circ_0001361 has been recognized as key regulators in various malignancies, but its roles in LUAD remain am...

    Authors: Hong-Yu Shen, Liu-Xi Shi, Lin Wang, Le-Ping Fang, Wei Xu, Ju-Qing Xu, Bo-Qiang Fan and Wei-Fei Fan
    Citation: Journal of Translational Medicine 2021 19:389

    The Correction to this article has been published in Journal of Translational Medicine 2021 19:476

  16. Pancreatic cancer is one of the most serious digestive malignancies. At present, there is an extreme lack of effective strategies in clinical treatment. The purpose of this study is to identify key genes and p...

    Authors: Yueqin Feng, Yuguan Jiang and Fengjin Hao
    Citation: Journal of Translational Medicine 2021 19:373
  17. As an important part of tumor immunotherapy for adjunct, therapeutic tumor vaccines have been effective against multiple solid cancers, while their efficacy against lower grade glioma (LGG) remains undefined. ...

    Authors: Liguo Ye, Long Wang, Ji’an Yang, Ping Hu, Chunyu Zhang, Shi’ao Tong, Zhennan Liu and Daofeng Tian
    Citation: Journal of Translational Medicine 2021 19:352
  18. DNA damage response plays critical roles in tumor pathogenesis and radiotherapy resistance. Protein phosphorylation is a critical mechanism in regulation of DNA damage response; however, the key mediators for ...

    Authors: Jia Liu, Jingyi Li, Zhao Sun, Yangmiao Duan, Fengqin Wang, Guangwei Wei and Jing-Hua Yang
    Citation: Journal of Translational Medicine 2021 19:339
  19. In recent years, long non-coding RNAs (lncRNAs) have attracted much attention because of its regulatory role in occurrence and progression of tumors, including triple-negative breast cancer (TNBC). LncRNA PITP...

    Authors: Bolong Liu, Pingbo Yao, Feng Xiao, Jianjin Guo, Lianghui Wu and Yong Yang
    Citation: Journal of Translational Medicine 2021 19:333
  20. Reversible enzymatic methylation of mammalian mRNA is widespread and serves crucial regulatory functions, but little is known to what degree chemical alkylators mediate overlapping modifications and whether ce...

    Authors: Kristian Lied Wollen, Lars Hagen, Cathrine B. Vågbø, Renana Rabe, Tobias S. Iveland, Per Arne Aas, Animesh Sharma, Bjørnar Sporsheim, Hilde O. Erlandsen, Vuk Palibrk, Magnar Bjørås, Davi M. Fonseca, Nima Mosammaparast and Geir Slupphaug
    Citation: Journal of Translational Medicine 2021 19:287
  21. Improved understanding of tumor immunology has enabled the development of therapies that harness the immune system and prevent immune escape. Numerous clinical trials and real-world experience has provided evi...

    Authors: Paolo A. Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A. Emens, Robert Ferris, Silvia C. Formenti, Jerome Galon, Samir N. Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos, Janis M. Taube, John Timmerman…
    Citation: Journal of Translational Medicine 2021 19:238